Clinical Trial Update: CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluated CPI-613 (Devimistat) in combination with chemoradiation for pancreatic adenocarcinoma. The study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Devimistat (CPI-613) (devimistat)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Pancreas Adenocarcinoma | Phase 1 | Status: TERMINATED